Lipid transfer proteins (LTP) and atherosclerosis

Atherosclerosis

Volumn 178, Issue 2, 2005, Pages 217-230

  Stein, O ^a   Stein, Y ^b  

^a HEBREW UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

ACAT; Atherosclerosis; CETP; HDL; LCAT; PLTP

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID TRANSFER PROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID; TAMOXIFEN; TORCETRAPIB;

ATHEROSCLEROSIS; CHOLESTEROL ESTERIFICATION; CLINICAL EXAMINATION; ENZYME INHIBITION; GENE OVEREXPRESSION; GENE TRANSFER; HUMAN; MEDICAL INFORMATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN TRANSPORT; RABBIT; REVIEW;

ABSORPTION; ANIMALS; ARTERIOSCLEROSIS; CARRIER PROTEINS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EPIDEMIOLOGIC STUDIES; GENE TRANSFER TECHNIQUES; GLYCOPROTEINS; HUMANS; MEMBRANE PROTEINS; MICE; OXIDATIVE STRESS; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEINS; QUINOLINES; RABBITS; STEROL O-ACYLTRANSFERASE;

EID: 13244266993     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.10.008     Document Type: Review

References (149)

1. V.L. Meiner, S. Cases, and H.M. Myers Disruption of the acyl-CoA:cholesterol acyltransferase gene in mice: evidence suggesting multiple cholesterol esterification enzymes in mammals Proc Natl Acad Sci USA 93 1996 14041 14046
2. K.K. Buhman, M. Accad, and S. Novak Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice Nat Med 6 12 2000 1341 1347
3. R.E. Temel, A.K. Gebre, J.S. Parks, and L.L. Rudel Compared with acyl-CoA:cholesterol O-acyltransferase (ACAT) 1 and lecithin:cholesterol acyltransferase, ACAT2 displays the greatest capacity to differentiate cholesterol from sitosterol J Biol Chem 278 48 2003 47594 47601
4. A. Rodriguez, and D.C. Usher Anti-atherogenic effects of the acyl-CoA:cholesterol acyltransferase inhibitor, avasimibe (CI-1011), in cultured primary human macrophages Atherosclerosis 161 1 2002 45 54
5. A.T. Lada, M. Davis, and C. Kent Identification of ACAT1- and ACAT2-specific inhibitors using a novel, cell-based fluorescence assay: individual ACAT uniqueness J Lipid Res 45 2 2004 378 386
6. S. Fazio, A.S. Major, and L.L. Swift Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages J Clin Invest 107 2 2001 163 171
7. S. Perrey, C. Legendre, and A. Matsuura Preferential pharmacological inhibition of macrophage ACAT increases plaque formation in mouse and rabbit models of atherogenesis Atherosclerosis 155 2 2001 359 370
8. J. Kusunoki, D.K. Hansoty, and K. Aragane Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice Circulation 103 21 2001 2604 2609
9. T. Chiwata, K. Aragane, and K. Fujinami Direct effect of an acyl-CoA:cholesterol acyltransferase inhibitor, F-1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice Br J Pharmacol 133 7 2001 1005 1012
10. Y. Azuma, K. Date, and K. Ohno NTE-122, an acyl-CoA:cholesterol acyltransferase inhibitor, prevents the progression of atherogenesis in cholesterol-fed rabbits Jpn J Pharmacol 86 1 2001 120 123
11. Y. Rival, D. Junquero, and F. Bruniquel Anti-atherosclerotic properties of the acyl-coenzyme A:cholesterol acyltransferase inhibitor F 12511 in casein-fed New Zealand rabbits J Cardiovasc Pharmacol 39 2 2002 181 191
12. D.J. Delsing, E.H. Offerman, and W. van Duyvenvoorde Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice Circulation 103 13 2001 1778 1786
13. T.M. Bocan, B.R. Krause, and W.S. Rosebury The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression Atherosclerosis 157 1 2001 97 105
14. F.J. Raal, A.D. Marais, and E. Klepack Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia Atherosclerosis 171 2 2003 273 279
15. J.C. Tardif, J. Gregoire, and J. Lesperance Design features of the avasimibe and progression of coronary lesions assessed by intravascular ultraSound (A-PLUS) clinical trial Am Heart J 144 4 2002 589 596
16. I. Namatame, H. Tomoda, S. Ishibashi, and S. Omura Antiatherogenic activity of fungal beauveriolides, inhibitors of lipid droplet accumulation in macrophages Proc Natl Acad Sci USA 101 3 2004 737 742
17. C.H. Thomas Yeung, L. Yang, Y. Huang, J. Wang, and Z.Y. Chen Dietary conjugated linoleic acid mixture affects the activity of intestinal acyl coenzyme A: cholesterol acyltransferase in hamsters Br J Nutr 84 6 2000 935 941
18. E.L. Willner, B. Tow, and K.K. Buhman Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice Proc Natl Acad Sci USA 100 3 2003 1262 1267
19. P. de Medina, B.L. Payre, and J. Bernad Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells J Pharmacol Exp Ther 308 3 2004 1165 1173
20. J. Reckless, J.C. Metcalfe, and D.J. Grainger Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice Circulation 95 6 1997 1542 1548
21. J.K. Williams, J.D. Wagner, Z. Li, D.L. Golden, and M.R. Adams Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys Arterioscler Thromb Vasc Biol 17 2 1997 403 408
22. A.C. Ross, K.J. Go, J.G. Heider, and G.H. Rothblat Selective inhibition of acyl coenzyme A:cholesterol acyltransferase by compound 58-035 J Biol Chem 259 2 1984 815 819
23. C.A. Argmann, C.H. Van Den Diepstraten, and C.G. Sawyez Transforming growth factor-beta1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants Arterioscler Thromb Vasc Biol 21 12 2001 2011 2018
24. K. Sugimoto, M. Tsujita, C.A. Wu, K. Suzuki, and S. Yokoyama An inhibitor of acyl CoA:cholesterol acyltransferase increases expression of ATP-binding cassette transporter A1 and thereby enhances the ApoA-l-mediated release of cholesterol from macrophages Biochim Biophys Acta 1636 1 2004 69 76
25. L.L. Rudel, R.G. Lee, and T.L. Cockman Acyl coenzyme A:cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis Curr Opin Lipidol 12 2 2001 121 127
26. T.Y. Chang, C.C. Chang, and S. Lin Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and -2 Curr Opin Lipidol 12 3 2001 289 296
27. A. Miyazaki, M. Sakai, Y. Sakamoto, and S. Horiuchi Acyl-coenzyme A:cholesterol acyltransferase inhibitors for controlling hypercholesterolemia and atherosclerosis Curr Opin Investig Drugs 4 9 2003 1095 1099
28. J.A. Glomset The mechanism of the plasma cholesterol esterification reaction: plasma fatty acid transferase Biochim Biophys Acta 65 1962 128 135
29. J.A. Glomset The plasma lecithins:cholesterol acyltransferase reaction J Lipid Res 9 1968 155 167
30. V.L.M. Lima, C.B.B. Coelho, J.F. Kennedy, J.S. Owen, and P.J. Dolphin Lecithin-cholesterol acyltransferase (LCAT) as a plasma glycoprotein: an overview Carbohydr Polym 55 2004 179 191
31. O.L. Francone, A. Gurakar, and C. Fielding Distribution and functions of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in plasma lipoproteins. Evidence for a functional unit containing these activities together with apolipoproteins A-I and D that catalyzes the esterification and transfer of cell-derived cholesterol J Biol Chem 264 1989 7066 7072
32. A. Steinmetz, and G. Utermann Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV J Biol Chem 260 February 25 (4) 1985 2258 2264
33. C.H. Chen, and J.J. Albers Activation of lecithin: cholesterol acyltransferase by apolipoproteins E-2, E-3, and A-IV isolated from human plasma Biochim Biophys Acta 836 1985 279 285
34. P.G. Frank, D. N'Guyen, and V. Franklin Importance of central alpha-helices of human apolipoprotein A-I in the maturation of high-density lipoproteins Biochemistry 37 1998 13902 13909
35. P.G. Frank, and Y.L. Marcel Apolipoprotein A-I: structure-function relationships J Lipid Res 41 2000 853 872
36. S. Roosbeek, B. Vanloo, and N. Duverger Three arginine residues in apolipoprotein A-1 are critical for activation of lecithin:cholesterol acyltransferase J Lipid Res 42 2001 31 40
37. K.H. Cho, D.M. Durbin, and A. Jonas Role of individual amino acids of apolipoprotein A-1 in the activation of lecithin:cholesterol acyltransferase and in HDL rearrangements J Lipid Res 42 2001 379 389
38. Y. Zhao, J. Wang, A.K. Gebre, J.W. Chisholm, and J.S. Parks Negative charge at amino acid 149 is the molecular determinant for substrate specificity of lecithin: cholesterol acyltransferase for phosphatidylcholine containing 20-carbon sn-2 fatty acyl chains Biochemistry 42 2003 13941 13949
39. K. Ikewaki, A. Matsunaga, and H. Han A novel two nucleotide deletion in the apolipoprotein A-1 gene, apoA-1 Shinbashi, associated with high density lipoprotein deficiency, corneal opacities, planar xanthomas, and premature coronary artery disease Atherosclerosis 172 2004 39 45
40. F. Peelman, J.L. Verschelde, and B. Vanloo Effects of natural mutations in lecithin:cholesterol acyltransferase on the enzyme structure and activity J Lipid Res 40 1999 59 69
41. M.N. Nanjee, J. Stocks, and C.J. Cooke A novel LCAT mutation (Phe382 → Val) in a kindred with familial LCAT deficiency and defective apolipoprotein B-100 Atherosclerosis 170 2003 105 113
42. K. Zhang, S. Zhang, and K. Zheng Novel P143L polymorphism of the LCAT gene is associated with dyslipidemia in Chinese patients who have coronary atherosclerotic heart disease Biochem Biophys Res Commun 318 2004 4 10
43. J.A. Kuivenhoven, H. Pritchard, and J. Hill The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes J Lipid Res 38 1997 191 205
44. T. Miida, B. Zhang, and K. Obayashi T13M mutation of lecithin-cholesterol acyltransferase gene causes fish-eye disease Clin Chim Acta 343 2004 201 208
45. J.W. Furbee Jr., J.K. Sawyer, and J.S. Parks Lecithin:cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice J Biol Chem 277 2002 3511 3519
46. J.W. Furbee Jr., O. Francone, and J.S. Parks In vivo contribution of LCAT to apolipoprotein B lipoprotein cholesteryl esters in LDL receptor and apolipoprotein E knockout mice J Lipid Res 43 2002 428 437
47. D.S. Ng, G.F. Maguire, and J. Wylie Oxidative stress is markedly elevated in lecithin:cholesterol acyltransferase-deficient mice and is paradoxically reversed in the apolipoprotein E knockout background in association with a reduction in atherosclerosis J Biol Chem 277 2002 11715 11720
48. T.M. Forte, G. Subbanagounder, and J.A. Berliner Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice J Lipid Res 43 2002 477 485
49. A. Mertens, P. Verhamme, and J.K. Bielicki Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis Circulation 107 2003 1640 1646
50. B. Foger, M. Chase, and M.J. Amar Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice J Biol Chem 274 52 1999 36912 36920
51. J.W. Furbee Jr., and J.S. Parks Transgenic overexpression of human lecithin: cholesterol acyltransferase (LCAT) in mice does not increase aortic cholesterol deposition Atherosclerosis 165 2002 89 100
52. Z. Nong, H. Gonzalez-Navarro, and M. Amar Hepatic lipase expression in macrophages contributes to atherosclerosis in apoE-deficient and LCAT-transgenic mice J Clin Invest 112 2003 367 378
53. D.B. Zilversmit, L.B. Hughes, and J. Balmer Stimulation of cholesterol ester exchange by lipoprotein-free rabbit plasma Biochim Biophys Acta 409 3 1975 393 398
54. N.M. Pattnaik, A. Montes, L.B. Hughes, and D.B. Zilversmit Cholesteryl ester exchange protein in human plasma isolation and characterization Biochim Biophys Acta 530 3 1978 428 438
55. J.F. Thompson, M.E. Lira, and L.K. Durham Polymorphisms in the CETP gene and association with CETP mass and HDL levels Atherosclerosis 167 2 2003 195 204
56. B.F. Asztalos, K.V. Horvath, and K. Kajinami Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency J Lipid Res 45 3 2004 448 455
57. B.F. Asztalos, C.H. Sloop, L. Wong, and P.S. Roheim Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-1-containing subpopulations Biochim Biophys Acta 1169 3 1993 291 300
58. B.F. Asztalos, P.S. Roheim, and R.L. Milani Distribution of ApoA-1-containing HDL subpopulations in patients with coronary heart disease Arterioscler Thromb Vasc Biol 20 12 2000 2670 2676
59. B.F. Asztalos, K.V. Horvath, and J.R. McNamara Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients Atherosclerosis 164 2 2002 361 369
60. J.D. Curb, R.D. Abbott, and B.L. Rodriguez A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly J Lipid Res 45 5 2004 948 953
61. J.F. Carlquist, J.B. Muhlestein, and B.D. Home The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease Am Heart J 146 6 2003 1007 1014
62. D.J. Freeman, N.J. Samani, and V. Wilson A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study Eur Heart J 24 20 2003 1833 1842
63. M.E. Brousseau, J.J. O'Connor Jr., and J.M. Ordovas Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial Arterioscler Thromb Vasc Biol 22 7 2002 1148 1154
64. J.M. Ordovas, L.A. Cupples, and D. Corella Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study Arterioscler Thromb Vasc Biol 20 5 2000 1323 1329
65. S. Blankenberg, H.J. Rupprecht, and C. Bickel AtheroGene investigators. Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease J Am Coll Cardiol 41 11 2003 1983 1989
66. G.J. de Grooth, K.E. Zerba, and S.P. Huang The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy J Am Coll Cardiol 43 5 2004 854 857
67. N. Barzilai, G. Atzmon, and C. Schechter Unique lipoprotein phenotype and genotype associated with exceptional longevity JAMA 290 15 2003 2030 2040
68. C. Bruce, D.S. Sharp, and A.R. Tall Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia J Lipid Res 39 5 1998 1071 1078
69. A. Goto, K. Sasai, and S. Suzuki Cholesteryl ester transfer protein and atherosclerosis in Japanese subjects: a study based on coronary angiography Atherosclerosis 159 1 2001 153 163
70. K. Okumura, H. Matsui, and H. Kamiya Differential effect of two common polymorphisms in the cholesteryl ester transfer protein gene on low-density lipoprotein particle size Atherosclerosis 161 2 2002 425 431
71. S. Kakko, M. Tamminen, and M. Paivansalo Variation at the cholesteryl ester transfer protein gene in relation to plasma high density lipoproteins cholesterol levels and carotid intima-media thickness Eur J Clin Invest 31 7 2001 593 602
72. S.M. Boekholdt, and J.F. Thompson Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease J Lipid Res 44 6 2003 1080 1093
73. Y. Friedlander, E. Leitersdorf, R. Vecsler, H. Funke, and J. Kark The contribution of candidate genes to the response of plasma lipids and lipoproteins to dietary challenge Atherosclerosis 152 1 2000 239 248
74. Y.S. Son, and D.B. Zilversmit Increased lipid transfer activities in hyperlipidemic rabbit plasma Arteriosclerosis 6 1986 345 351
75. Y. Stein, Y. Dabach, G. Hollander, and O. Stein Cholesteryl ester transfer activity in hamster plasma: increase by fat and cholesterol rich diets Biochim Biophys Acta 1042 1990 138 141
76. O. Stein, Y. Dabach, and G. Hollander Relative resistance of the hamster to aortic atherosclerosis in spite of prolonged vitamin E deficiency and dietary hypercholesterolemia. Putative effect of increased HDL? Biochim Biophys Acta 1299 1996 216 222
77. O. Stein, G. Halperin, and Y. Stein Cholesteryl ester efflux from extracellular and cellular elements of the arterial wall. Model systems in culture with cholesteryl linoleyl ether Arteriosclerosis 6 1986 70 78
78. O. Stein, Y. Dabach, G. Hollander, and Y. Stein Removal of cholesteryl ester from hepatic reticuloendothelial cells in vivo is not enhanced by plasma cholesteryl ester transfer protein Biochim Biophys Acta 1081 1991 238 240
79. O. Stein, Y. Dabach, and G. Hollander Reverse cholesterol transport in mice expressing simian cholesteryl ester transfer protein Atherosclerosis 164 1 2002 73 78
80. P. Parini, and L.L. Rudel Is there a need for cholesteryl ester transfer protein inhibition? Arterioscler Thromb Vasc Biol 23 3 2003 374 375
81. P.J. Barter, H.B. Brewer Jr., and M.J. Chapman Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis Arterioscler Thromb Vasc Biol 23 2 2003 160 167
82. P.M. Cazita, J.A. Berti, and C. Aoki Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice J Lipid Res 44 1 2003 33 40
83. P.S. MacLean, J.F. Bower, and S. Vadlamudi Cholesteryl ester transfer protein expression prevents diet-induced atherosclerotic lesions in male db/db mice Arterioscler Thromb Vasc Biol 23 2003 1412 1415
84. C.J. Fielding, and R.J. Havel Cholesteryl ester transfer protein: friend or foe? J Clin Invest 97 12 1996 2687 2688
85. K. Hirano, S. Yamashita, and Y. Matsuzawa Pros and cons of inhibiting cholesteryl ester transfer protein Curr Opin Lipidol 11 6 2000 589 596
86. G.F. Watts The yin and yang of cholesteryl ester transfer protein and atherosclerosis Clin Sci (Lond) 103 6 2002 595 597
87. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 8934 1994 1383 1389
88. J. Shepherd, S.M. Cobbe, and I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 20 1995 1301 1307
89. F.M. Sacks, M.A. Pfeffer, and L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 335 14 1996 1001 1009
90. J.J. Genest, J.R. McNamara, D.N. Salem, and E.J. Schaefer Prevalence of risk factors in men with premature coronary artery disease Am J Cardiol 67 15 1991 1185 1189
91. H. Okarnoto, F. Yonemori, and K. Wakitani A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits Nature 406 6792 2000 203 207
92. Z. Huang, A. Inazu, A. Nohara, T. Higashikata, and H. Mabuchi Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia Clin Sci (Lond) 103 6 2002 587 594
93. G.J. de Grooth, J.A. Kuivenhoven, and A.F. Stalenhoef Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study Circulation 105 18 2002 2159 2165
94. E. Shimoji, B. Zhang, P. Fan, and K. Saku Inhibition of cholesteryl ester transfer protein increases serum apolipoprotein (apo) A-1 levels by increasing the synthesis of apo A-1 in rabbits Atherosclerosis 172 2 2004 247 257
95. K. Asayama, H. Hayashibe, and K. Dobashi Increased serum cholesteryl ester transfer protein in obese children Obes Res 10 6 2002 439 446
96. C.F. Ebenbichler, M. Laimer, and S. Kaser Relationship between cholesteryl ester transfer protein and atherogenic lipoprotein profile in morbidly obese women Arterioscler Thromb Vasc Biol 22 9 2002 1465 1469
97. R.W. Clark, T.A. Sutfin, and R.B. Ruggeri Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib Arterioscler Thromb Vasc Biol 24 2004 1 9
98. M.E. Brousseau, E.J. Schaefer, and M.L. Wolfe Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol N Engl J Med 350 2004 1505 1515
99. C.W. Rittershaus, D.P. Miller, and L.J. Thomas Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis Arterioscler Thromb Vasc Biol 20 2000 2106 2112
100. M.H. Davidson, K. Maki, and D. Umporowicz The safety and immunogenicity of a CETP vaccine in healthy adults Atherosclerosis 169 2003 113 120
101. M. Miller, J. Rhyne, S. Hamlette, J. Birnbaum, and A. Rodriguez Genetics of HDL regulation in humans Curr Opin Lipidol 14 2003 273 279
102. E.S. Tai, and C.E. Tan Genes, diet and serum lipid concentrations: lessons from ethnically diverse populations and their relevance to coronary heart disease in Asia Curr Opin Lipidol 15 2004 5 12
103. S.M. Boekholdt, and J.F. Thompson Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease J Lipid Res 44 2003 1080 1093
104. A. Ritsch, and J.R. Patsch Cholesteryl ester transfer protein: gathering momentum as a genetic marker and as drug target Curr Opin Lipidol 14 2003 173 179
105. K.W. Wirtz, and D.B. Zilversmit Partial purification of phospholipid exchange protein from beef heart FEBS Lett 7 1 1970 44 46
106. P.A. Mak, H.R. Kast-Woelbern, A.M. Anisfeld, and P.A. Edwards Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors J Lipid Res 43 12 2002 2037 2041
107. T. Oka, T. Kujiraoka, and M. Ito Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive J Lipid Res 41 10 2000 1651 1657
108. M. Karkkainen, T. Oka, and V.M. Olkkonen Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP) J Biol Chem 277 18 2002 15413 15418
109. S. Siggins, M. Jauhiainen, V.M. Olkkonen, J. Tenhunen, and C. Ehnholm PLTP secreted by HepG2 cells resembles the high-activity PLTP form in human plasma J Lipid Res 44 9 2003 1698 1704
110. S. Siggins, M. Karkkainen, and J. Tenhunen Quantitation of the active and low-active forms of human plasma phospholipid transfer protein by ELISA J Lipid Res 45 2 2004 387 395
111. M.C. Cheung, G. Wolfbauer, H. Kennedy, B.G. Brown, and J.J. Albers Plasma phospholipid transfer protein activity in patients with low HDL and cardiovascular disease treated with simvastatin and niacin Biochim Biophys Acta 1537 2 2001 117 124
112. A. Schlitt, C. Bickel, and P. Thumma High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease Arterioscler Thromb Vasc Biol 23 10 2003 1857 1862
113. H. Yatsuya, K. Tamakoshi, and H. Hattori Serum phospholipid transfer protein mass as a possible protective factor for coronary heart diseases Circ J 68 1 2004 11 16
114. C.M. Desrumaux, P.A. Mak, and W.A. Boisvert Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells J Lipid Res 44 8 2003 1453 1461
115. B.A. Laffitte, S.B. Joseph, and M. Chen The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions Mol Cell Biol 23 6 2003 2182 2191
116. K.D. O'Brien, S. Vuletic, and T.O. McDonald Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis Circulation 108 3 2003 270 274
117. G. Wolfbauer, J.J. Albers, and J.F. Oram Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipoprotein apolipoproteins Biochim Biophys Acta 1439 1 1999 65 76
118. H.M. Colhoun, L.M. Scheek, and M.B. Rubens Lipid transfer protein activities in type 1 diabetic patients without renal failure and nondiabetic control subjects and their association with coronary artery calcification Diabetes 50 3 2001 652 659
119. H.M. Colhoun, M.R. Taskinen, and J.D. Otvos Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes Diabetes 51 11 2002 3300 3305
120. I.J. Jonkers, A.H. Smelt, and H. Hattori Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy J Lipid Res 44 8 2003 1462 1469
121. M.C. Cheung, R.H. Knopp, and B. Retzlaff Association of plasma phospholipid transfer protein activity with IDL and buoyant LDL: impact of gender and adiposity Biochim Biophys Acta 1587 1 2002 53 59
122. S.J. Murdoch, S.E. Kahn, J.J. Albers, J.D. Brunzell, and J.Q. Pumell PLTP activity decreases with weight loss: changes in PLTP are associated with changes in subcutaneous fat and FFA but not IAF or insulin sensitivity J Lipid Res 44 9 2003 1705 1712
123. J.J. Albers, G. Wolfbauer, and M.C. Cheung Functional expression of human and mouse plasma phospholipid transfer protein: effect of recombinant and plasma PLTP on HDL subspecies Biochim Biophys Acta 1258 1 1995 27 34
124. S. Vuletic, L.W. Jin, and S.M. Marcovina Widespread distribution of PLTP in human CNS: evidence for PLTP synthesis by glia and neurons, and increased levels in Alzheimer's disease J Lipid Res 44 6 2003 1113 1123
125. K. Krapfenbauer, B.C. Yoo, S.H. Kim, N. Cairns, and G. Lubec Differential display reveals downregulation of the phospholipid transfer protein (PLTP) at the mRNA level in brains of patients with Down syndrome Life Sci 68 18 2001 2169 2179
126. S. Rust, M. Rosier, and H. Funke Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1 Nat Genet 22 4 1999 352 355
127. J.F. Oram, G. Wolfbauer, A.M. Vaughan, C. Tang, and J.J. Albers Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells J Biol Chem 278 52 2003 52379 52385
128. R.P. Dullaart, and A. van Tol Role of phospholipid transfer protein and prebeta-high density lipoproteins in maintaining cholesterol efflux from Fu5AH cells to plasma from insulin-resistant subjects Scand J Clin Lab Invest 61 1 2001 69 74
129. M. Lee, J. Metso, M. Jauhiainen, and P.T. Kovanen Degradation of phospholipid transfer protein (PLTP) and PLTP-generated pre-beta-high density lipoprotein by mast cell chymase impairs high affinity efflux of cholesterol from macrophage foam cells J Biol Chem 278 15 2003 13539 13545
130. S. Ehnholm, K.W. van Dijk, and B. van't Hof Adenovirus mediated overexpression of human phospholipid transfer protein alters plasma HDL levels in mice J Lipid Res 39 6 1998 1248 1253
131. B. Foger, S. Santamarina-Fojo, and R.D. Shamburek Plasma phospholipid transfer protein. Adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL J Biol Chem 272 43 1997 27393 27400
132. S. Jaari, K.W. van Dijk, and V.M. Olkkonen Dynamic changes in mouse lipoproteins induced by transiently expressed human phospholipid transfer protein (PLTP): importance of PLTP in prebeta-HDL generation Comp Biochem Physiol 128 4 2001 781 792
133. M. Bouly, D. Masson, and B. Gross Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate J Biol Chem 276 28 2001 25841 25847
134. G. Cao, T.P. Beyer, and X.P. Yang Phospholipid transfer protein is regulated by liver X receptors in vivo J Biol Chem 277 42 2002 39561 39565
135. J. Lie, R. de Crom, and T. van Gent Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion J Lipid Res 43 11 2002 1875 1880
136. J. Lie, R. De Crom, and T. van Gent Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis in spite of lowering apolipoprotein B containing lipoproteins J Lipid Res 45 5 2004 805 811
137. S.M. Post, R. de Crom, R. van Haperen, A. van Tol, and H.M. Princen Increased fecal bile acid excretion in transgenic mice with elevated expression of human phospholipid transfer protein Arterioscler Thromb Vasc Biol 23 5 2003 892 897
138. J.J. Albers, A.Y. Tu, and B. Paigen Transgenic mice expressing human phospholipid transfer protein have increased HDL/non-HDL cholesterol ratio Int J Clin Lab Res 26 4 1996 262 267
139. X. Jiang, O.L. Francone, and C. Bruce Increased prebeta-high density lipoprotein, apolipoprotein A1, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein A1 transgenes J Clin Invest 98 10 1996 2373 2380
140. R. van Haperen, A. van Tol, and P. Vermeulen Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice Arterioscler Thromb Vasc Biol 20 4 2000 1082 1088
141. R. van Haperen, A. van Tol, and T. van Gent Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein J Biol Chem 277 50 2002 48938 48943
142. X.P. Yang, D. Yan, and C. Qiao Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression Arterioscler Thromb Vasc Biol 23 9 2003 1601 1607
143. A.R. Tall, and F. Lalanne Phospholipid transfer protein and atherosclerosis Arterioscler Thromb Vasc Biol 23 9 2003 1484 1485
144. X.C. Jiang, S. Qin, and C. Qiao Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency Nat Med 7 7 2001 847 852
145. X.C. Jiang, A.R. Tall, and S. Qin Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E J Biol Chem 277 35 2002 31850 31856
146. J. Huuskonen, V.M. Olkkonen, M. Jauhiainen, and C. Ehnholm The impact of phospholipid transfer protein (PLTP) on HDL metabolism Atherosclerosis 155 2 2001 269 281
147. X.C. Jiang The effect of phospholipid transfer protein on lipoprotein metabolism and atherosclerosis Front Biosci 7 2002 d1634 d1641
148. A. van Tol Phospholipid transfer protein Curr Opin Lipidol 13 2 2002 135 139
149. J.J. Albers, and M.C. Cheung Emerging roles for phospholipid transfer protein in lipid and lipoprotein metabolism Curr Opin Lipidol 15 3 2004 255 260